Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA-Reference-Cited by-同舟云学术

Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA

Published:2019-05 Issue:13 Volume:15 Page:1493-1504
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Lim Jonathan¹,Samuelsen Carl²,Golembesky Amanda²,Shrestha Sulena³,Wang Li³,Griebsch Ingolf²

Affiliation:

1. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA

2. Boehringer Ingelheim International GmbH, Ingelheim, Germany

3. STATinMED Research, Plano, TX 75024, USA

Abstract

Aim: Evaluate duration of therapy among patients treated with afatinib or erlotinib as first-line therapy for non-small-cell lung cancer (NSCLC). Materials & methods: NSCLC patients initiating afatinib or erlotinib between 2014 and 2017 were identified in three large claims databases in the USA. Propensity score matching was conducted to compare the duration of treatment between patients by treatment. Results: Patients prescribed afatinib had a significantly longer median duration of treatment compared with those prescribed erlotinib (12.1 vs 9.9 months; p = 0.035) and experienced a 14% reduction in risk of discontinuing therapy (adjusted hazard ratio: 0.86; CI: 0.75–0.99). Conclusion: First-line treatment duration in a real-world setting was significantly longer for patients prescribed afatinib compared with erlotinib.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2019-0052

Reference63 articles.

1. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version 1-2019 (2018). www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

5. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overview;Current Medical Research and Opinion;2023-03-24

2. Real‐world treatment patterns of metastatic non‐small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors;Cancer Medicine;2022-06-15

3. Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence;Journal of Oncology;2021-12-18

4. Healthcare Resource Utilization and Baseline Characteristics of Patients With Generalized Pustular Psoriasis: Real-World Results From a Large US Database of Multiple Commercial Medical Insurers;Journal of Psoriasis and Psoriatic Arthritis;2021-06-09

5. Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis;Clinical Lung Cancer;2020-11